Abstract
The non-lysosomal glucosylceramidase GBA2 catalyzes the hydrolysis of glucosylceramide to glucose and ceramide. Loss of GBA2 function results in accumulation of glucosylceramide. Mutations in the human GBA2 gene have been associated with hereditary spastic paraplegia (HSP) and autosomal-recessive cerebellar ataxia (ARCA). Patients suffering from these disorders exhibit impaired locomotion and neurological abnormalities. GBA2 mutations found in these patients have been proposed to impair GBA2 function. However, the molecular mechanism underlying the occurrence of mutations in the GBA2 gene and the development of locomotor dysfunction is not well-understood. In this review, we aim to summarize recent findings regarding mutations in the GBA2 gene and their impact on GBA2 function in health and disease.
Introduction
Lipids are major constituents of cellular membranes in archaea, bacteria, and eukaryotes. Cellular membranes not only fulfill a barrier function to the environment, but also provide a platform for cellular processes. Various lipid species with different physical properties form functionally and structurally distinct lipid layers, which change dynamically and, in turn, determine the functional output of a cell. Defects in the lipid homeostasis alter cellular functions, resulting in severe diseases, e.g., neurological dysfunction. Among them are the autosomal-recessive cerebellar ataxia (ARCA) and hereditary spastic paraplegia (HSP), which share common symptoms with cerebellar signs typical for ataxia and spasticity and show a disease onset in early childhood. Furthermore, the underlying genes, cellular pathways, and disease mechanisms seem to be common (Synofzik and Schüle, ). For both, ARCA and HSP, patients with mutations in the human GBA2 gene have been identified (Hammer et al., ; Martin et al., ; Citterio et al., ; Votsi et al., ; Sultana et al., ; Table 1). GBA2 is a beta-glucosidase, which degrades the glycosphingolipid glucosylceramide (GlcCer) to glucose and ceramide. Loss of GBA2 function results in accumulation of GlcCer and dysregulation of the lipid homeostasis (Raju et al., ; Schonauer et al., ). However, the molecular mechanism underlying the occurrence of mutations in the GBA2 gene and the development of locomotor dysfunction is not well-understood. Here, we summarize the recent findings of GBA2-dependent control of GlcCer homeostasis and its role in controlling motor function in health and disease.
Table 1
| Mutation | Alleles | Human GBA2 | Mouse GBA2 | Associated disease | References | |
|---|---|---|---|---|---|---|
| Variants with an amino-acid substitution | 2618G>A | homozygous | R873H | R864H | Autosomal-recessive cerebellar ataxia | Hammer et al., |
| 2201G>A | Homozygous | R734H | R725H | Autosomal-recessive cerebellar ataxia | Votsi et al., | |
| 2048G>C | Homozygous | G683R | G674R | Hereditary spastic paraplegia | Citterio et al., | |
| 1888C>T | Homozygous | R630W | R621W | Hereditary spastic paraplegia | Martin et al., | |
| 1780G>C | Homozygous | D594H | D585H | Autosomal-recessive cerebellar ataxia | Votsi et al., | |
| 1255T>G | Heterozygous, co-segregated with 2608C>T | F419V | F410V | Hereditary spastic paraplegia | Sultana et al., | |
| Truncated variants | 2608C>T | Heterozygous, co-segregated with 1255T>G | R870* | Q861* | Hereditary spastic paraplegia | Sultana et al., |
| 1528_1529del | homozygous | M510V*16 | M501A*16 | Marinesco-Sjögren-Like Syndrome | Haugarvoll et al., | |
| 1471_1474dupGGCA | Heterozygous, co-segregated with 518G>A | T492R*9 | T483R*9 | Hereditary spastic paraplegia | Martin et al., | |
| 1017C>T | Homozygous | R340* | R331* | Autosomal-recessive cerebellar ataxia | Hammer et al., | |
| 700C>T | Homozygous | R234* | R225* | Hereditary spastic paraplegia | Martin et al., | |
| 518G>A | Heterozygous, co-segregated with 1471_1474dupGGCA | W173* | W164* | Hereditary spastic paraplegia | Martin et al., | |
| 363C>A | Homozygous | Y121* | Y112* | Autosomal-recessive cerebellar ataxia | Hammer et al., |
Mutations in the human GBA2 gene associated with locomotor dysfunction.
Indicates a stop codon.
Glucosylceramide metabolism and GBA2 function
The three major membrane lipid species are phospholipids, cholesterol, and sphingolipids (van Meer et al., ). Of these three, sphingolipids are the most complex lipid species. Ceramide is the building block to generate glycosylated sphingolipids known as glycosphingolipids. Glycosphingolipids are tremendously heterogeneous and vary (1) in the length of the fatty acid linked to the sphingosine molecule, (2) in the hydroxylation and saturation state of the fatty acid, and (3) in the oligosaccharide attached to the lipid backbone (Stults et al., ). Altogether, glycosphingolipids comprise more than 300 different lipids in mammals. The simplest glycosphingolipids galactosylceramide (GalCer) and GlcCer are synthesized by specific galactosyl- and glucosyltransferases that use UDP-galactose or UDP-glucose, respectively, and link the sugar moiety to ceramide via an O-glycosidic bond (Figure 1; Basu et al., ; Morell et al., ; Ichikawa et al., ). GlcCer is the precursor for more complex glycosphingolipids: globosides contain more sugar side-chains attached to ceramide, whereas gangliosides contain additional sialic acid moieties linked to ceramide. These complex glycosphingolipids are important structural components of the membrane, since they cluster in specific microdomains known as lipid rafts, and build a platform to gather certain proteins, e.g., ion channels and receptors (Simons and Toomre, ; Dart, ). Thus, glycosphingolipids play a key role in controlling cellular signaling, and regulating the levels of the glycosphingolipid precursor, GlcCer, is crucial to maintain cellular signaling. Degradation of GlcCer is catalyzed by glucosylceramidases, namely the lysosomal GBA1, also called glucocerebrosidase, the non-lysosomal membrane-associated GBA2, and the cytosolic Klotho-related glucosylceramidase GBA3, with the latter playing only a minor role in glycosphingolipid homeostasis (Ho and O'Brien, ; Matern et al., ; Hayashi et al., ). These glucosylceramidases hydrolyze GlcCer to release the monosaccharide glucose from the ceramide backbone (Figure 1). GBA1 activity was not only the first to be identified, but is also the one that has been most comprehensively studied. It conveys the main hydrolysis of GlcCer in the lysosome and mutations in the GBA1 gene result in a severe lysosomal storage disorder called Gaucher disease (Brady et al., ; Grace et al., ). Only in the last 10 years, the physiological function of GBA2 and its contribution to GlcCer degradation has been identified. The human GBA2 gene is encoded on chromosome 9 and spans 17 exons. The GBA2 protein consists of 927 amino acids and is highly conserved among different species (87% sequence identity between human GBA2 and mouse GBA2). GBA2 is ubiquitously expressed, with highest expression levels found in liver, brain, and testis (van Weely et al., ; Matern et al., ). The enzyme was initially identified as a bile-acid β-glucosidase (Matern et al., ), but later shown to cleave GlcCer (Matern et al., ; Boot et al., ). Although GBA1 and GBA2 share the same substrate GlcCer, they do not show any sequence homology, and are localized in different cellular compartments: GBA1 is localized in the lysosome, whereas GBA2 activity has been first associated with the plasma membrane (Aureli et al., , ); however, reports analyzing its cellular localization demonstrate that GBA2 is a membrane-associated protein at the cytoplasmic site of the ER and Golgi membrane (Körschen et al., ). The two activities can be distinguished by their different pH optima (GBA1: pH 4–4.5, GBA2: pH 5.5–6; van Weely et al., ; Aureli et al., ; Körschen et al., ). Furthermore, GBA2 can be pharmacologically blocked by iminosugars [N-deoxynojirimycin (AMP-DNM), N-butyldeoxynojirimycin (NB-DNJ) and N-butyldeoxygalactonojirimycin (NB-DGJ)] that mimic the cyclic saccharide, but lack an O-glycosidic bond for enzyme cleavage (Ridley et al., ). GBA2 not only hydrolyzes GlcCer, it also exhibits a transglucosylation activity, transferring glucose to cholesterol. Thus, the glucose moiety released by the cleavage of GlcCer can be used by GBA2 to form glucocholesterol (GlcChol). Vice versa, GlcChol can be deglycosylated by GBA2 to synthesize GlcCer (Marques et al., ).
Figure 1
Loss of GBA2 results in the accumulation of GlcCer, in particular in those tissues where GBA2 expression is highest, i.e., testis, brain, and liver (Yildiz et al., ). The predominant phenotype associated with the genetic loss of GBA2 in a mouse model was observed in male reproduction: male GBA2 knockout mice were subfertile due to a sperm morphological defect occurring during spermatogenesis, a condition called globozoospermia (Yildiz et al., ). A similar phenotype was observed when GBA2 was pharmacologically inhibited (van der Spoel et al., ; Walden et al., ). On a molecular level, this phenotype was shown to be caused by the accumulation of GlcCer in sperm and Sertoli cells, which alters the lipid stacking of the plasma membrane and, in turn, dysregulates the cytoskeletal dynamics, impairing sperm development (Yildiz et al., ; Raju et al., ). Furthermore, GBA2 knockout mice also displayed a defect in liver regeneration when undergoing partial hepatectomy (Gonzalez-Carmona et al., ), which seems to be due to an IL-6-dependent change in the STAT3 signaling cascade (Gonzalez-Carmona et al., ). However, the distinct role of GBA2 in the brain, where its expression level is also high, has not been identified. Whereas mutations in the GBA2 gene in human patients have been associated with impaired locomotion and neurological abnormalities, the analysis of GBA2-knockout mouse models did not reveal neurological symptoms or a defect in locomotor function yet.
The role of glycosphingolipids in the central nervous system
Glycosphingolipids - especially gangliosides - are highly abundant in neurons, where they undergo constant changes in their localization pattern and overall content in the plasma membrane (Aquino et al., ). Ganglioside content in the brain increases during development, more precisely the amount of more complex species of the a- and b-series (Figure 1; Svennerholm et al., ). Fluctuation in the expression of the distinct glucosyltransferases and glucohydrolases allows the cells to adapt to differentiation processes (Aureli et al., ). In fact, GBA2 expression increases during neuronal differentiation (Aureli et al., ). Morphological changes during neuronal differentiation and axon growth are also accompanied by changes in the lipid content of the cell (Aureli et al., ). Due to their structural asymmetry with the hydrophobic ceramide inserted into the external leaflet of the membrane and the oligosaccharide facing the extracellular space, gangliosides play a crucial role in restructuring of the membrane: The complex hydrophilic oligosaccharide moieties induce a spatial segregation of the lipids across the membrane, whereby a positive membrane curvature is generated (Brocca and Sonnino, ). Moreover, lipid separation promotes the formation of microdomains, so-called lipid rafts, consisting of gangliosides and cholesterol (Simons and Toomre, ). Loss of glycosphingolipid synthesis in neurons leads to severe cellular defects: inhibition of ceramide synthesis in hippocampal neurons and Purkinje cells impairs axon and dendritic growth, respectively (Harel and Futerman, ; Furuya et al., ). Furthermore, GlcCer synthesis was demonstrated to be a prerequisite for growth factor bFGF- and laminin-induced axon growth (Boldin and Futerman, ). In vivo, perturbation of the glycosphingolipid homeostasis leads to neurological dysfunctions. Knockout mouse-models of distinct synthases of the ganglio series resembled comparable phenotypes: Loss of gangliosides in GM2/GM3 synthase double-knockout mice led to severe ataxia and limb weakness due to axon degeneration (Yamashita et al., ). Mice devoid of the GM2/GD2 and GD3 synthase also revealed gait abnormalities in line with tremor, resulting from neurodegeneration affecting the cerebellum. Knockout of GM2/GD2 synthase alone also caused neuropathy in mice (Chiavegatto et al., ; Ohmi et al., ). Thus, maintenance of glycosphingolipid homeostasis is required for proper neuron function.
Mutations in the GBA1 or 2 gene associated with neurological disorders
Mutations in the GBA1 gene have been associated with Parkinson's disease (PD), the second most common neurodegenerative disorder after Alzheimer's disease, characterized by slow movements accompanied by decrement and degradation of repetitive movements (Mitsui et al., ; Sidransky et al., ; Shachar et al., ; Blanz and Saftig, ; Migdalska-Richards and Schapira, ). Homozygous mutations in GBA1 cause Gaucher disease, but an increased risk in developing PD has not only been observed for Gaucher disease patients, but already in heterozygous carriers (Migdalska-Richards and Schapira, ). Carriers of a GBA1 mutation contain an up to 30-fold higher risk of developing PD and at least 7–10% of PD patients carry a GBA1 mutation (Migdalska-Richards and Schapira, ). However, the underlying molecular mechanism is still ill-defined. Different hypotheses have been proposed how GBA1 mutations promote the development of PD. PD belongs to a group of diseases commonly referred to as synucleinopathies, which are characterized by the presence of Lewy bodies and α-synuclein in neurites. A shift of α-synuclein from the monomeric to the oligomeric toxic and aggregated form has been shown to underlie PD progression (Blanz and Saftig, ; Migdalska-Richards and Schapira, ). One model describes a direct interaction between the mutated GBA1 protein and α-synuclein, leading to α-synuclein accumulation and aggregation (Sidransky and Lopez, ). Another model proposes that decreased GBA1 activity, leading to lysosomal dysfunction, and accumulation of GlcCer and its related lipid metabolites affect α-synuclein trafficking, processing, and clearance, promoting α-synuclein aggregation and oligomer formation (Sidransky and Lopez, ; Blanz and Saftig, ; Migdalska-Richards and Schapira, ). Based on these models, strategies aiming to increase either the expression, stability, or delivery of GBA1 to the lysosomes are likely to decrease the α-synuclein burden, and may be used as a treatment for PD.
The correlation between mutations in the GBA2 gene and movement disorders is less well-characterized. ARCA patients suffer from problems in balance and limb coordination, dysarthria, increased tone in the limbs and often, in later stages, pronounced limb spasticity (Fogel and Perlman, ). In 2013, homozygosity mapping and whole-exome sequencing results of three Tunisian families, including seven patients suffering from ARCA of unknown genetic origin, were published. Patients were initially diagnosed according to their predominant ataxic symptoms at disease onset. However, during disease progression, they also developed spasticity of the lower and upper limbs (Hammer et al., ). All of them harbored mutations in the GBA2 gene: Two families contained a mutation in exon 5 (c.1017C>T), resulting in the truncated protein variant R340*, lacking the C-terminal beta-glucosidase domain (Figure 2). The third family carried a mutation in exon 17 (c.2618G>A), resulting in the amino-acid exchange R873H (Figure 2). For both mutations, only homozygous carriers were affected. Additional screening of 21 Tunisian individuals, suffering from cerebellar ataxia of unknown genetic cause, revealed a third mutation in exon 2 of the GBA2 gene in three siblings (c.363C>A), resulting in a truncated GBA2 protein Y121*, lacking both the C-terminal beta-glucosidase and the N-terminal domain (Figure 2). All identified GBA2 mutations were absent in 50 healthy Tunisian families and in 330 controls of the Human Genome Diversity Project (HGDP; Hammer et al., ). In 2014, two more GBA2 mutations in three ARCA patients in a Cypriot family were identified using homozygosity mapping and exome sequencing of chromosome 9: mutations in exon 11 (c.1780G>C) and in exon 15 (c.2201G>A) resulted in the amino-acid substitution D594H and R734H, respectively (Figure 2; Votsi et al., ). Patients were diagnosed with spasticity of the lower limbs and cerebellar symptoms. Heterozygous carriers in the family were not affected, indicating that the mutations are only pathogenic in the homozygous state. None of these mutations were found in 52 control Cypriot individuals (Votsi et al., ).
Figure 2
HSP patients suffer from dysfunction or degeneration of motor neurons, resulting in locomotor dysfunction such as spasticity, brisk reflexes, and pyramidal weakness of the lower limbs (Harding, ; Schüle and Schöls, ). Multiple loci have been mapped to this largely heterogeneous group of disorders with spastic paraplegia 46 on chromosome 9, containing the hGBA2 gene, being one of them. A number of mutations in the GBA2 gene have been associated with HSP (Martin et al., ; Citterio et al., ; Sultana et al., ). Screening of 46 families of both Italian and African origin, suffering from complicated forms of HSP, revealed one patient with severe spasticity of the lower limbs and mild cerebellar signs carrying the mutation c.2048G>C in exon 13 on both alleles of the GBA2 gene, resulting in the amino-acid exchange G683R (Figure 2). This gene variant was tested against 600 controls of Italian origin and the genome databases dbSNP and 1,000 Genomes, but only occurred in the affected subject (Citterio et al., ). Furthermore, one missense and three truncated GBA2 variants were identified in the genome of patients suffering from HSP accompanied by cerebellar ataxia (Martin et al., ). The amino-acid substitution R630W (1888C>T; Figure 2) in exon 12 was identified in a homozygous state in six individuals of two families, but in none of the 519 healthy controls (Martin et al., ). In a third family, the mutation c.700C>T in exon 4 was found in one HSP patient in a homozygous state, resulting in the truncated protein hGBA2 R234*, lacking the C-terminal beta-glucosidase domain and part of the N-terminal domain (Figure 2). The heterozygous mutation c.518G>A in exon 3 and c.1471_1474dupGGCA in exon 9, resulting in the truncated variants W173* and T492R*9, respectively, co-segregated with the disease in another family (Martin et al., ). The truncated proteins lack either both the C-terminal beta-glucosidase and the N-terminal domain or only the C-terminal domain (Figure 2).
Recently, mutations in the GBA2 gene have also been associated with the Marinesco-Sjögren-Like Syndrome, with patients showing both typical ARCA and HSP disease characteristics (Haugarvoll et al., ). Whole-exome sequencing revealed the homozygous mutation c.1528_1529del, resulting in the amino-acid substitution M510V*16 (Figure 2) in two Norwegian families and one unrelated affected subject, but not in any of the tested 500 control exomes nor 192 control blood samples (Haugarvoll et al., ). A summary of all mutations is presented in Table 1.
So far, only one mutation has been functionally characterized in vivo in an animal model. In a zebrafish model, GBA2 expression was severely reduced by injecting antisense zGba2 mRNA into zebrafish larvae. This resulted in a malformed tail and a defect in motor coordination in 12.5% of injected animals (Martin et al., ). A more detailed behavioral analysis (touch-response test) showed that also injected zebrafish lacking the curly tail phenotype exhibited motor defects. Immunohistochemical analyses of motor neurons in the spine revealed a defect in axonal growth. Co-injection of human wild-type GBA2 mRNA rescued this axonal phenotype, whereas the mutant R630W failed to compensate for the loss of zGBA2 (Martin et al., ). However, a detailed analysis of the different mutant GBA2 proteins and their physiological relevance in a mammalian animal model is still missing. First attempts have been made to characterize the different mutations in a heterologous expression system. The mutant GBA2 variants Y121*, W173*, R234*, R340*, F419V, R870*, D594H, R630W, G683R, and R873H all displayed reduced expression levels compared to wild-type GBA2 (Sultana et al., ). In a luciferase-based activity assay of transfected COS-7 and HeLa cells, all GBA2 mutants were null mutations without any activity compared to the wild-type GBA2 protein. Thus, human patients carrying these mutations might lack GBA2 activity (Sultana et al., ).
So far, it is not known how these mutations affect GBA2 function on a molecular level. The recently published crystal structure of a bacterial β-glucosidase helped to understand the consequence of GBA2 mutations on protein function. The bacterial β-glucosidase TxGH116, expressed in Thermoanaerobacterium xylanolyticum, belongs to the same enzyme family GH116 as GBA2 (Charoenwattanasatien et al., ). The sequence encoding the catalytic domain of TxGH116 bears 40% sequence identity to GBA2. Amino-acid residue D508 and R786 corresponding to D594 and R873 in hGBA2, respectively, face the catalytic cleft of the enzyme, and are probably involved in forming hydrogen bonds with the 6-OH and 3-OH group of the glucose, respectively (Charoenwattanasatien et al., ). Thus, mutating one of these amino acids could directly interfere with the catalytic activity of GBA2. The amino acid G683 of hGBA2 seems to be located in a loop, which is important for the acid/base and the sugar binding. Mutations in this region might perturb loop formation and, thereby GBA2 activity. Furthermore, R630 in hGBA2 seems to undergo electrostatic interactions with the anionic carboxylate of E555 and D631, which are in close proximity. The loss of net charge at this position caused by an amino-acid substitution to tryptophan and the subsequent loss of amino-acid interaction might destabilize GBA2 (Charoenwattanasatien et al., ). Solving the crystal structure of a mammalian GBA2 protein will reveal whether the homology modeling according to the bacterial protein structure reliably predicts the structure of hGBA2 and allows to verify disease-causing mutations. So far, data suggest that the mutations found in human GBA2 gene are loss-of-function mutations. Loss of GBA2 activity results in accumulation of GlcCer, which is supposed to change the lipid organization in the plasma membrane to a more ordered state and promote actin polymerization (Raju et al., ). The effect of GlcCer accumulation on membrane stacking and actin dynamics has been mainly studied in fibroblasts or germ cells during sperm development. Whether similar mechanisms occur in neurons, underlying the development of neuropathy in the absence of GBA2, is not known. Studies investigating the cellular phenotypes after loss of GBA1 activity, GBA2 activity, or both revealed that (a) there is a complex interplay between the two beta-glucosidases, and (b) that accumulation of GlcCer cannot be the sole determinant for the development of cellular pathologies (Mistry et al., ; Schonauer et al., ). In fact, concomitant loss of GBA2 activity in a GBA1-mouse model for Gaucher disease rescued the clinical phenotypes although glycosphingolipid levels were increased (Mistry et al., ). Furthermore, loss of GBA1 activity down-regulated GBA2 activity in fibroblasts from patients with Gaucher disease. This was conveyed through sphingosine, the cytotoxic metabolite accumulating in Gaucher cells through the action of GBA2: sphingosine bound to GBA2 and inhibited its activity (Schonauer et al., ). The role of sphingosine in the development of neuropathy in GBA2 knockout mice has not been investigated yet.
Concluding remarks
Altogether, GBA2 function and homeostasis seem to be important for brain function and motor coordination. However, whether the defects are only occurring in neurons or also in skeletal muscle is not known. Furthermore, the underlying molecular mechanism is enigmatic. The analysis is hampered by the fact that in GBA2-knockout mouse models, neither neurological symptoms nor locomotor dysfunction has been observed yet. Thus, more detailed studies in mammalian animal models and state-of-the art biophysical and biochemical approaches will be needed to unravel the physiological function of GBA2 and GlcCer in the brain and their role in motor coordination in health and disease.
Statements
Author contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work, and approved it for publication.
Funding
This work was supported by the Deutsche Forschungsgemeinschaft (DFG): SFB645, the Bonn Excellence Cluster for ImmunoSensation, SPP1726, SPP1926, and by the Boehringer Ingelheim Foundation and the Fritz-Thyssen Foundation.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AquinoD. A.BisbyM. A.LedeenR. W. (1987). Bidirectional transport of gangliosides, glycoproteins and neutral glycosphingolipids in the sensory neurons of rat sciatic nerve. Neuroscience20, 1023–1029. 10.1016/0306-4522(87)90260-0
2
AureliM.GrittiA.BassiR.LobertoN.RiccaA.ChigornoV.et al. (2012). Plasma membrane-associated glycohydrolases along differentiation of murine neural stem cells. Neurochem. Res.37, 1344–1354. 10.1007/s11064-012-0719-z
3
AureliM.LobertoN.LanteriP.ChigornoV.PrinettiA.SonninoS. (2011). Cell surface sphingolipid glycohydrolases in neuronal differentiation and aging in culture. J. Neurochem.116, 891–899. 10.1111/j.1471-4159.2010.07019.x
4
AureliM.MasilamaniA. P.IlluzziG.LobertoN.ScandroglioF.PrinettiA.et al. (2009). Activity of plasma membrane beta-galactosidase and beta-glucosidase. FEBS Lett. 583, 2469–2473. 10.1016/j.febslet.2009.06.048
5
AureliM.SamaraniM.LobertoN.BassiR.MurdicaV.PrioniS.et al. (2014). The glycosphingolipid hydrolases in the central nervous system. Mol. Neurobiol.50, 76–87. 10.1007/s12035-013-8592-6
6
BasuS.KaufmanB.RosemanS. (1968). Enzymatic synthesis of ceramide-glucose and ceramide-lactose by glycosyltransferases from embryonic chicken brain. J. Biol. Chem. 243, 5802–5804.
7
BlanzJ.SaftigP. (2016). Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance. J. Neurochem. 139 (Suppl. 1), 198–215. 10.1111/jnc.13517
8
BoldinS.FutermanA. H. (1997). Glucosylceramide synthesis is required for basic fibroblast growth factor and laminin to stimulate axonal growth. J. Neurochem.68, 882–895. 10.1046/j.1471-4159.1997.68020882.x
9
BootR. G.VerhoekM.Donker-KoopmanW.StrijlandA.van MarleJ.OverkleeftH. S.et al. (2007). Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2. J. Biol. Chem.282, 1305–1312. 10.1074/jbc.M610544200
10
BradyR. O.KanferJ. N.ShapiroD. (1965). Metabolism of Glucocerebrosides. ii. evidence of an enzymatic deficiency in gaucher's disease. Biochem. Biophys. Res. Commun. 18, 221–225. 10.1016/0006-291X(65)90743-6
11
BroccaP.SonninoS. (1997). Dynamics and spatial organization of surface gangliosides. Trends Glycosci. Glycotechnol. 9, 433–445. 10.4052/tigg.9.433
12
CharoenwattanasatienR.PengthaisongS.BreenI.MutohR.SansenyaS.HuaY.et al. (2016). Bacterial beta-glucosidase reveals the structural and functional basis of genetic defects in human glucocerebrosidase 2 (GBA2). ACS Chem. Biol.11, 1891–1900. 10.1021/acschembio.6b00192
13
ChiavegattoS.SunJ.NelsonR. J.SchnaarR. L. (2000). A functional role for complex gangliosides: motor deficits in GM2/GD2 synthase knockout mice. Exp. Neurol. 166, 227–234. 10.1006/exnr.2000.7504
14
CitterioA.ArnoldiA.PanzeriE.D'AngeloM. G.FilostoM.DilenaR.et al. (2014). Mutations in CYP2U1, DDHD2 and GBA2 genes are rare causes of complicated forms of hereditary spastic paraparesis. J. Neurol.261, 373–381. 10.1007/s00415-013-7206-6
15
DartC. (2010). Lipid microdomains and the regulation of ion channel function. J. Physiol.588, 3169–3178. 10.1113/jphysiol.2010.191585
16
FinnR. D.AttwoodT. K.BabbittP. C.BatemanA.BorkP.BridgeA. J.et al. (2017). InterPro in 2017-beyond protein family and domain annotations. Nucleic Acids Res.45, D190–D199. 10.1093/nar/gkw1107
17
FogelB. L.PerlmanS. (2007). Clinical features and molecular genetics of autosomal recessive cerebellar ataxias. Lancet Neurol.6, 245–257. 10.1016/S1474-4422(07)70054-6
18
FuruyaS.OnoK.HirabayashiY. (1995). Sphingolipid biosynthesis is necessary for dendrite growth and survival of cerebellar Purkinje cells in culture. J. Neurochem.65, 1551–1561. 10.1046/j.1471-4159.1995.65041551.x
19
Gonzalez-CarmonaM. A.SandhoffR.TackeF.VogtA.WeberS.CanbayA. E.et al. (2012). Beta-glucosidase 2 knockout mice with increased glucosylceramide show impaired liver regeneration. Liver Int.32, 1354–1362. 10.1111/j.1478-3231.2012.02841.x
20
GraceM. E.NewmanK. M.ScheinkerV.Berg-FussmanA.GrabowskiG. A. (1994). Analysis of human acid beta-glucosidase by site-directed mutagenesis and heterologous expression. J. Biol. Chem. 269, 2283–2291.
21
HammerM. B.Eleuch-FayacheG.SchottlaenderL. V.NehdiH.GibbsJ. R.ArepalliS. K.et al. (2013). Mutations in GBA2 cause autosomal-recessive cerebellar ataxia with spasticity. Am. J. Hum. Genet.92, 245–251. 10.1016/j.ajhg.2012.12.012
22
HardingA. E. (1983). Classification of the hereditary ataxias and paraplegias. Lancet1, 1151–1155. 10.1016/S0140-6736(83)92879-9
23
HarelR.FutermanA. H. (1993). Inhibition of sphingolipid synthesis affects axonal outgrowth in cultured hippocampal neurons. J. Biol. Chem. 268, 14476–14481.
24
HaugarvollK.JohanssonS.RodriguezC. E.BomanH.HaukanesB. I.BrulandO.et al. (2017). GBA2 mutations cause a marinesco-sjogren-like syndrome: genetic and biochemical studies. PLoS ONE12:e0169309. 10.1371/journal.pone.0169309
25
HayashiY.OkinoN.KakutaY.ShikanaiT.TaniM.NarimatsuH.et al. (2007). Klotho-related protein is a novel cytosolic neutral beta-glycosylceramidase. J. Biol. Chem.282, 30889–30900. 10.1074/jbc.M700832200
26
HoM. W.O'BrienJ. S. (1971). Gaucher's disease: deficiency of ‘acid’ -glucosidase and reconstitution of enzyme activity in vitro. Proc. Natl. Acad. Sci. U.S.A.68, 2810–2813. 10.1073/pnas.68.11.2810
27
IchikawaS.SakiyamaH.SuzukiG.HidariK. I.HirabayashiY. (1996). Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis. Proc. Natl. Acad. Sci. U.S.A.93, 12654. 10.1073/pnas.93.10.4638
28
KörschenH. G.YildizY.RajuD. N.SchonauerS.BönigkW.JansenV.et al. (2013). The non-lysosomal beta-glucosidase GBA2 is a non-integral membrane-associated protein at the endoplasmic reticulum (ER) and Golgi. J. Biol. Chem.288, 3381–3393. 10.1074/jbc.M112.414714
29
MarquesA. R.MirzaianM.AkiyamaH.WisseP.FerrazM. J.GasparP.et al. (2016). Glucosylated cholesterol in mammalian cells and tissues: formation and degradation by multiple cellular beta-glucosidases. J. Lipid Res. 57, 451–463. 10.1194/jlr.M064923
30
MartinE.SchuleR.SmetsK.RastetterA.BoukhrisA.LoureiroJ. L.et al. (2013). Loss of function of glucocerebrosidase GBA2 is responsible for motor neuron defects in hereditary spastic paraplegia. Am. J. Hum. Genet.92, 238–244. 10.1016/j.ajhg.2012.11.021
31
MaternH.GartzenR.MaternS. (1992). Beta-glucosidase activity towards a bile acid glucoside in human liver. FEBS Lett.314, 183–186. 10.1016/0014-5793(92)80970-R
32
MaternH.HeinemannH.LeglerG.MaternS. (1997). Purification and characterization of a microsomal bile acid beta-glucosidase from human liver. J. Biol. Chem.272, 11261–11267. 10.1074/jbc.272.17.11261
33
Migdalska-RichardsA.SchapiraA. H. (2016). The relationship between glucocerebrosidase mutations and Parkinson disease. J. Neurochem. 139 (Suppl. 1), 77–90. 10.1111/jnc.13385
34
MistryP. K.LiuJ.SunL.ChuangW. L.YuenT.YangR.et al. (2014). Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease. Proc. Natl. Acad. Sci. U.S.A.111, 4934–4939. 10.1073/pnas.1400768111
35
MitsuiJ.MizutaI.ToyodaA.AshidaR.TakahashiY.GotoJ.et al. (2009). Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch. Neurol.66, 571–576. 10.1001/archneurol.2009.72
36
MorellP.Costantino-CeccariniE.RadinN. S. (1970). The biosynthesis by brain microsomes of cerebrosides containing nonhydroxy fatty acids. Arch. Biochem. Biophys.141, 738–748. 10.1016/0003-9861(70)90192-X
37
OhmiY.TajimaO.OhkawaY.MoriA.SugiuraY.FurukawaK.et al. (2009). Gangliosides play pivotal roles in the regulation of complement systems and in the maintenance of integrity in nerve tissues. Proc. Natl. Acad. Sci. U.S.A.106, 22405–22410. 10.1073/pnas.0912336106
38
RajuD.SchonauerS.HamzehH.FlynnK. C.BradkeF.Vom DorpK.et al. (2015). Accumulation of glucosylceramide in the absence of the beta-glucosidase GBA2 alters cytoskeletal dynamics. PLoS Genet. 11:e1005063. 10.1371/journal.pgen.1005063
39
RidleyC. M.ThurK. E.ShanahanJ.ThillaiappanN. B.ShenA.UhlK.et al. (2013). β-Glucosidase 2 (GBA2) activity and imino sugar pharmacology. J. Biol. Chem. 288, 26052–26066. 10.1074/jbc.M113.463562
40
SchonauerS.KörschenH. G.PennoA.RennhackA.BreidenB.SandhoffK.et al. (2017). Identification of a feedback loop involving beta-glucosidase 2 and its product sphingosine sheds light on the molecular mechanisms in Gaucher disease. J. Biol. Chem. 292, 6177–6189. 10.1074/jbc.M116.762831
41
SchüleR.SchölsL. (2011). Genetics of hereditary spastic paraplegias. Semin. Neurol.31, 484–493. 10.1055/s-0031-1299787
42
ShacharT.Lo BiancoC.RecchiaA.WiessnerC.Raas-RothschildA.FutermanA. H. (2011). Lysosomal storage disorders and Parkinson's disease: gaucher disease and beyond. Mov. Disord.26, 1593–1604. 10.1002/mds.23774
43
SidranskyE.LopezG. (2012). The link between the GBA gene and parkinsonism. Lancet Neurol.11, 986–998. 10.1016/S1474-4422(12)70190-4
44
SidranskyE.SamaddarT.TayebiN. (2009). Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology73, 1424–1425. 10.1212/WNL.0b013e3181b28601
45
SimonsK.ToomreD. (2000). Lipid rafts and signal transduction. Nat. Rev. Mol. Cell. Biol.1, 31–39. 10.1038/35036052
46
StultsC. L.SweeleyC. C.MacherB. A. (1989). Glycosphingolipids: structure, biological source, and properties. Meth. Enzymol.179, 167–214. 10.1016/0076-6879(89)79122-9
47
SultanaS.ReichbauerJ.SchuleR.MochelF.SynofzikM.van der SpoelA. C. (2015). Lack of enzyme activity in GBA2 mutants associated with hereditary spastic paraplegia/cerebellar ataxia (SPG46). Biochem. Biophys. Res. Commun.465, 35–40. 10.1016/j.bbrc.2015.07.112
48
SvennerholmL.BostromK.FredmanP.ManssonJ. E.RosengrenB.RynmarkB. M. (1989). Human brain gangliosides: developmental changes from early fetal stage to advanced age. Biochim. Biophys. Acta1005, 109–117. 10.1016/0005-2760(89)90175-6
49
SynofzikM.SchüleR. (2017). Overcoming the divide between ataxias and spastic paraplegias: shared phenotypes, genes, and pathways. Mov. Disord.32, 332–345. 10.1002/mds.26944
50
van der SpoelA. C.JeyakumarM.ButtersT. D.CharltonH. M.MooreH. D.DwekR. A.et al. (2002). Reversible infertility in male mice after oral administration of alkylated imino sugars: a nonhormonal approach to male contraception. Proc. Natl. Acad. Sci. U.S.A.99, 17173–17178. 10.1073/pnas.262586099
51
van MeerG.VoelkerD. R.FeigensonG. W. (2008). Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell Biol.9, 112–124. 10.1038/nrm2330
52
van WeelyS.BrandsmaM.StrijlandA.TagerJ. M.AertsJ. M. (1993). Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease. Biochim. Biophys. Acta1181, 55–62. 10.1016/0925-4439(93)90090-N
53
VotsiC.Zamba-PapanicolaouE.MiddletonL. T.PantzarisM.ChristodoulouK. (2014). A novel GBA2 gene missense mutation in spastic ataxia. Ann. Hum. Genet.78, 13–22. 10.1111/ahg.12045
54
WaldenC. M.SandhoffR.ChuangC. C.YildizY.ButtersT. D.DwekR. A.et al. (2007). Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis. J. Biol. Chem.282, 32655–32664. 10.1074/jbc.M702387200
55
YamashitaT.WuY. P.SandhoffR.WerthN.MizukamiH.EllisJ. M.et al. (2005). Interruption of ganglioside synthesis produces central nervous system degeneration and altered axon-glial interactions. Proc. Natl. Acad. Sci. U.S.A.102, 2725–2730. 10.1073/pnas.0407785102
56
YildizY.MaternH.ThompsonB.AllegoodJ. C.WarrenR. L.RamirezD. M.et al. (2006). Mutation of beta-glucosidase 2 causes glycolipid storage disease and impaired male fertility. J. Clin. Invest.116, 2985–2994. 10.1172/J.C.I.29224
Summary
Keywords
beta-glucosidase, GBA2, glucosylceramide, glycosphingolipids, locomotor function
Citation
Woeste MA and Wachten D (2017) The Enigmatic Role of GBA2 in Controlling Locomotor Function. Front. Mol. Neurosci. 10:386. doi: 10.3389/fnmol.2017.00386
Received
17 September 2017
Accepted
06 November 2017
Published
28 November 2017
Volume
10 - 2017
Edited by
Alexandre Henriques, Spedding Research Solutions, France
Reviewed by
Hyunsoo Shawn Je, Duke-NUS Medical School, Singapore; Stefan Hauser, Deutsche Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE), Germany
Updates
Copyright
© 2017 Woeste and Wachten.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Dagmar Wachten dwachten@uni-bonn.de
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.